WINTON GROUP Ltd Takes $2.15 Million Position in PharMerica Co. (PMC)

WINTON GROUP Ltd bought a new stake in shares of PharMerica Co. (NYSE:PMC) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 73,380 shares of the company’s stock, valued at approximately $2,150,000. WINTON GROUP Ltd owned approximately 0.24% of PharMerica as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in PMC. Royce & Associates LP lifted its stake in shares of PharMerica by 966.5% during the 2nd quarter. Royce & Associates LP now owns 426,600 shares of the company’s stock valued at $11,198,000 after buying an additional 386,600 shares in the last quarter. Victory Capital Management Inc. lifted its stake in PharMerica by 40.1% in the 2nd quarter. Victory Capital Management Inc. now owns 1,294,142 shares of the company’s stock worth $33,971,000 after purchasing an additional 370,266 shares in the last quarter. SG Americas Securities LLC lifted its stake in PharMerica by 3,799.6% in the 3rd quarter. SG Americas Securities LLC now owns 281,007 shares of the company’s stock worth $8,234,000 after purchasing an additional 273,801 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new stake in PharMerica in the 3rd quarter worth $7,031,000. Finally, Gabelli Funds LLC purchased a new stake in PharMerica in the 3rd quarter worth $5,645,000. Institutional investors own 89.97% of the company’s stock.

PharMerica Co. (NYSE:PMC) remained flat at $$29.25 during trading on Monday. The stock had a trading volume of 150,300 shares, compared to its average volume of 276,211. PharMerica Co. has a twelve month low of $22.00 and a twelve month high of $29.50. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.79 and a current ratio of 2.58. The stock has a market capitalization of $910.27, a P/E ratio of 15.15, a P/E/G ratio of 1.27 and a beta of 0.83.

PharMerica (NYSE:PMC) last posted its earnings results on Thursday, November 9th. The company reported $0.46 earnings per share for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.03). PharMerica had a return on equity of 10.94% and a net margin of 0.83%. The business had revenue of $595.10 million during the quarter, compared to the consensus estimate of $596.80 million. analysts forecast that PharMerica Co. will post 1.92 earnings per share for the current year.

PMC has been the topic of several research analyst reports. Zacks Investment Research cut shares of PharMerica from a “buy” rating to a “hold” rating in a research note on Wednesday, October 4th. ValuEngine upgraded shares of PharMerica from a “hold” rating to a “buy” rating in a research note on Tuesday, October 31st. KeyCorp cut shares of PharMerica to an “overweight” rating in a research note on Tuesday, August 8th. Finally, Barrington Research cut shares of PharMerica from an “outperform” rating to an “underperform” rating in a research note on Wednesday, August 9th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $30.50.

WARNING: “WINTON GROUP Ltd Takes $2.15 Million Position in PharMerica Co. (PMC)” was originally reported by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at https://www.com-unik.info/2017/12/04/winton-group-ltd-takes-2-15-million-position-in-pharmerica-co-pmc.html.

About PharMerica

Institutional Ownership by Quarter for PharMerica (NYSE:PMC)

What are top analysts saying about PharMerica Co.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for PharMerica Co. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit